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Abstract The purpose of this phase III clinical trial was to
compare two different extracellular contrast agents, 1.0 M
gadobutrol and 0.5 M gadopentate dimeglumine, for
magnetic resonance imaging (MRI) in patients with known
or suspected focal renal lesions. Using a multicenter,
single-blind, interindividual, randomized study design,
both contrast agents were compared in a total of 471
patients regarding their diagnostic accuracy, sensitivity,
and specificity to correctly classify focal lesions of the
kidney. To test for noninferiority the diagnostic accuracy
rates for both contrast agents were compared with CT
results based on a blinded reading. The average diagnostic
accuracy across the three blinded readers (‘average reader’)
was 83.7% for gadobutrol and 87.3% for gadopentate
dimeglumine. The increase in accuracy from precontrast to
combined precontrast and postcontrast MRI was 8.0% for
gadobutrol and 6.9% for gadopentate dimeglumine. Sen-
sitivity of the average reader was 85.2% for gadobutrol and
88.7% for gadopentate dimeglumine. Specificity of the
average reader was 82.1% for gadobutrol and 86.1% for
gadopentate dimeglumine. In conclusion, this study
documents evidence for the noninferiority of a single i.v.
bolus injection of 1.0 M gadobutrol compared with 0.5 M
gadopentate dimeglumine in the diagnostic assessment of
renal lesions with CE-MRI.
Keywords Gadobutrol . Gadopentate dimeglumine .
Renal lesions . MRI . Diagnostic differentiation .
Noninferiority
Abbreviations Bw: body weight . FAS: full analysis set .
FP: false positive . FN: false negative . FOV: field of view .
GE: gradient echo . MRI: magnetic resonance imaging .
PPS: per protocol set . SOT: standard of truth . SE: spin
echo . TN: true negative . TP: true positive
Introduction
Magnetic resonance imaging (MRI) has been shown to be
highly sensitive for the detection and characterization of
abdominal lesions including those in the liver, pancreas,
and kidney. Therefore, MRI often has direct implications
for patient management (surgical vs. nonsurgical treat-
ment) [1]. MRI is increasingly used in clinical routine to
differentiate between malignant and nonmalignant renal
tumors and is considered a complimentary modality to
computed tomography (CT) and ultrasonography (US).
The use of contrast agents in renal MRI offers additional
advantages for the diagnostic assessment of renal diseases
and is well established. The use of gadopentetate
dimeglumine (0.5 M Gd-DTPA, Magnevist®, Bayer
Schering Pharma) in combination with fat-saturation (FS)
techniques has been shown to be superior to unenhanced
MR imaging for detection and characterization of renal
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lesions [2]. Furthermore, 0.5 M gadopentate dimeglumine
may also provide the detection of functional kidney
derangement [3, 4] and allow for selective direct imaging
of the entire urinary tract [5].
Various 0.5 M nonspecific extracellular gadolinium
chelates1 are commercially available and have been
investigated for contrast-enhanced (CE)-MRI of different
body areas. It is widely assumed that these contrast agents
have a comparable efficacy, although only limited results
from direct comparative studies are available. These 0.5 M
gadolinium chelates belong to the first generation of
nonspecific extracellular Gd-chelates. However, a second
generation of commercially available MR contrast agents,
e.g., 0.5 M Gd-chelates with weak protein-binding proper-
ties (Gd-BOPTA, MultiHance®, Bracco) or the highly
concentrated 1.0 M macrocyclic Gd-chelate (gadobutrol,
Gadovist®, Bayer Schering Pharma), are increasingly used
in clinical routine following approval.
Due to its more compact bolus profile, 1.0 M gadobutrol
is well suited for dynamic imaging, such as first-pass MR
angiography and perfusion imaging [6–14]. It is also well
suited for standard MRI techniques (e.g., imaging of focal
disease in different body regions) with comparable efficacy
to other 0.5 M extracellular Gd-chelates, as the concentra-
tion of the contrast agent has no impact on the extracellular
distribution, including the distribution in lesions. Gadobu-
trol is therefore expected to provide diagnostic information
to classify benign and malignant lesions comparable to
0.5 M Gd-chelates.
Since 2006 gadolinium-based contrast agents have
increasingly been suspected to be one potential trigger
for a rare but serious condition, called nephrogenic
systemic fibrosis (NSF) [15, 16]. NSF has only been seen
in patients with severe renal impairment, most of whom
underwent dialysis, and in isolated cases in patients with
acute renal failure [17].
The purpose of this phase III clinical study was to
investigate the diagnostic efficacy of gadobutrol-enhanced
MRI for the classification of known or suspected focal
renal lesions as compared with 0.5 M gadopentate
dimeglumine. To test for noninferiority of 1.0 M gadobu-
trol-enhanced MRI in comparison with 0.5 M gadopentate
dimeglumine-enhanced MRI the diagnostic accuracy rates
for both contrast agents were compared with a predefined
standard of truth (SOT).
Material and methods
Study design and population
In order to meet the criteria of evidence-based medicine the
clinical trial was performed as a multicenter, randomized,
single-blind, interindividually controlled parallel group
study in a routine patient population. Patients with known
or suspected renal lesions who had undergone or were
planned for CT evaluation within 1 month before or after
the MRI examination were eligible for the study. Thus each
patient underwent both computed tomography (CT) and
contrast-enhanced MRI of the kidney. Regarding the
contrast-enhanced MRI, patients were randomized to
receive either gadobutrol or gadopentate dimeglumine
(1:1 randomization). A written informed consent was
obtained from each patient before they entered the study,
and the institutional review boards of all involved centers
approved the study.
Exclusion criteria were: age under 18 years, general
contraindications to MRI, clinical instability, surgery or
intervention within 4 weeks or scheduled for the 28-h
safety follow-up period, acute renal failure, pregnancy, and
lactation. Patients who had received any investigational
drug or systemic kidney tumor therapy within the previous
14 days or within 15 half-lives of the drug and patients who
had received any contrast medium within 24 h before or
who were scheduled to do so within 28 h of study injection
were also excluded. Additionally, patients with renal
lesions that could be sufficiently diagnosed by diagnostic
procedures other than CT or MRI (e.g., cysts) were
excluded.
Contrast agents
1.0 M gadobutrol (Gd-BT-DO3A, Gadovist®, Bayer
Schering Pharma AG, Berlin, Germany) is a gadolinium-
based hydrophilic, neutral (nonionic) macrocyclic contrast
agent. The steady-state volume of distribution indicates a
predominantly extracellular distribution. The terminal half-
life is approximately 1.5 h in healthy subjects [18].
Gadobutrol has a high complex stability owing to the
kinetic stability characteristic for macrocyclic agents. The
kinetic dissociation half-life is T1/2=24 h (pH=1), which
can be extrapolated to a T1/2 of over 1,000 years at pH=7.4
[19]. The T1-relaxivity (r1) is 5.2±0.3 l mmol−1 s−1, the
T2-relaxivity (r2) is 6.1±0.3 l mmol−1 s−1 (in plasma, at
1.5 T and 37°C) [20]. Gadobutrol has shown an excellent
renal tolerance in patients suffering from renal impairment
or those with end-stage renal failure under hemodialysis
treatment [21–23]. As of December 2007 there are no
reports on NSF in association with the administration of
gadobutrol in the peer-reviewed literature.
0.5 M gadopentetate dimeglumine (Gd-DTPA, Magne-
vist®, 0.5 mol Gd l−1, Bayer Schering Pharma AG, Berlin,
Germany) as a standard extracellular paramagnetic MR
contrast agent served as a reference agent with a proven
excellent efficacy and safety profile [24]. The T1- and T2-
relaxivities in plasma (at 1.5 T and 37°C) are somewhat
lower compared with gadobutrol (r1=4.1±0.2 l mmol−1 s−1,
r2=4.6±0.8 l mmol−1 s−1) [20]. As of December 2007 there
1 For example, Omniscan® (Gadodiamide) GE Healthcare, Pro-
Hance® (Gadoteridol) Bracco, Dotarem® (Gd-DOTA) Guerbet
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are reports on NSF in association with the administration of
gadopentate dimeglumine in the peer-reviewed literature
[25, 26]. Since June 2007 gadopentate dimeglumine is
contraindicated for the use in patients suffering from severe
renal impairment (GFR<30 ml min−1) in Europe (i.e., after
this study was conducted).
MRI sequences
MRI examinations comprising precontrast, dynamic con-
trast-enhanced, and delayed contrast-enhanced sequences
were obtained at a field strength of 1.5 T on MR systems
from different manufacturers.
The precontrast sequence (transversal orientation) in-
cluded a T2-TSE- and a T1-SE- or T1-GE-weighted
sequence without FS covering both kidneys (slice thick-
ness 5–8 mm, matrix ≥256×192, field of view (FOV)
≤400 mm). In addition, a T1 SE or GE sequence with fat
suppression was performed with sequence parameters that
were comparable except for the matrix (≥256×128).
In both groups, contrast agents were injected as an
intravenous bolus at a dose of 0.1 mmol Gd kg−1 bw with
anMR-compatible power injector. To allow for comparable
gadolinium delivery rates the injection speed was adapted
to the concentration of the injected contrast agent, e.g.,
1.0 ml s−1 for the 1.0 M gadobutrol and 2.0 ml s−1 for the
0.5 M gadopentate dimeglumine. A dynamic contrast-
enhanced T1-weighted sequence covering both kidneys
(coronal orientation) was acquired before and 20–30, 50–
60, and 160–180 s following the injection. GE or
multiplanar turbo-GE sequences with or without fat
suppression or alternatively 3D GRE sequences could be
applied during a breathhold period (slice thickness ≤5 mm
without gap, matrix ≥256×160, FOV ≤400 mm; in the case
of 3D sequences with a reconstruction interval of 5 mm).
Delayed contrast-enhanced T1-weighted sequences
(transversal acquisition, with and without FS) were
obtained 4–5 min following the injection.
Standard of truth procedure
A CT examination to establish the correct diagnosis of the
renal lesions was required for all patients; this was regarded
as the standard of truth (SOT). Both nonenhanced and
contrast-enhanced CT images (CE-CT) (preferably spiral
CT) of both kidneys had to be performed within 4 weeks
before or following the MRI procedure. A bolus injection
of ≥80 ml nonionic contrast agent was required, preferably
injected by a power injector. CE-CT had to be obtained
during a time frame of 1–5 min postinjection with a slice
thickness of up to 8 mm (preferably ≤5 mm). Where CT
was indeterminate regarding the classification of lesions,
additional tests or surgery were requested to establish
diagnosis. If surgery (e.g., nephrectomy, partial/hemine-
phrectomy, enucleation) or surgical exploration was
performed and respective histopathological results were
available, these results replaced the CT diagnosis as SOT
for the respective lesions.
Evaluation
MR images
MR image datasets were evaluated in a blinded reading by
three independent radiologists with expertise in abdominal
MRI as an off-site, central evaluation. Neither the
radiologists nor their institutions were involved in the on-
site part of the study. The blinded reading was divided into
three separate sessions: (1) precontrast (T1 and T2) MRI,
(2) contrast-enhanced MRI, (3) combined precontrast (T1
and T2) and contrast-enhanced MRI. In order to reduce
bias, readers were given no information concerning patient
population, indication/clinical question, center-related in-
formation, or details of the study protocol. An interval of at
least 3 weeks between each of the three reading sessions
was fixed to avoid recall bias. The readers had to detect and
classify the renal lesions as either malignant, benign, not
assessable, or no lesion for MRI.
CT images (SOT)
Blinded reading of the CT studies was performed as an
off-site, central evaluation by one independent certified
radiologist with expertise in abdominal CT imaging.
The radiologist and his respective institution were not
involved in the clinical part of the study. The reader was
provided with clinical information, e.g., age and sex,
reason for referral, genitourinary medical and surgical
history, but was blinded to center-related information,
details of the study protocol, and the clinical imaging
results. All identified lesions had to be classified as
malignant or benign in order to be included for any
SOT-based analysis.
Lesion tracking
The blinded reading of the MRI and CT examinations was
complemented with a lesion-tracking session by an inde-
pendent radiologist experienced in abdominal imaging,
using only the renal maps. The objective of the lesion
tracking was to guarantee an unambiguous assignment of
the lesions to the respective SOT diagnosis. The blinded
reader had to compare the renal maps derived from the
SOT procedures with those from the blinded off-site and
the clinical on-site readings of the MR images. This
procedure was performed to ensure that each lesion was
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assigned correctly on the renal maps from both SOT and
MR images.
Statistical analysis
Primary efficacy variable was the noninferiority of 1.0 M
gadobutrol to 0.5 M gadopentate dimeglumine in terms of
accuracy, using a 95% confidence interval approach on a
per-lesion basis for the per protocol set (PPS), i.e., for all
patients who concluded the study without major protocol
deviations. Diagnostic accuracy is an overall measure of
diagnostic efficacy, which determines the probability that a
test result reflects the true disease state of a patient. The
lesion classification resulting from study MRI was
compared with that of the SOT in order to determine the
classification outcome (TP, FN, FP, TN). Lesions not
classified by SOTwere excluded from these classifications
and from all other evaluations. The accuracy rate for lesion
classification of the MRI was defined as the number of
lesions with TP or TN ratings divided by the total number
of SOT lesions [27].
Descriptive statistics (N, mean, standard deviation,
median, minimum, and maximum) were performed for
quantitative variables and frequency counts, and percen-
tages by category were given for qualitative variables.
Two-sided 95% confidence interval (CIs) were prepared
where appropriate.
Noninferiority was statistically evaluated by testing at a
significance level α=0.025 the null hypothesis (H0:
accuracygadobutrol−accuracygadopentate ≤−Δ) against the
alternative hypothesis (H1: accuracygadobutrol −
accuracygadopentate >−Δ), whereΔ describes the acceptable
noninferiority threshold. The result for an ‘average reader’
was calculated from the results of the three blinded readers
for each group. A differenceΔ of <10% for the readers and
the average reader was prospectively defined to character-
ize statistical significance of noninferiority. In addition,
increases in diagnostic accuracy from precontrast MRI to
the combined precontrast and postcontrast MRI were
determined. For this evaluation, a differenceΔ of <4% was
prospectively defined as the threshold for significance of
noninferiority for readers and the average reader.
Furthermore, sensitivity2 and specificity,3 as well as
increases of sensitivity and specificity from precontrast
MRI to the combined precontrast and postcontrast MRI,
were determined. No threshold for statistical significance
was prospectively defined for the sensitivity and specificity
datasets.
Descriptive statistics were performed for all safety
variables, including AE data and vital signs.
Results
A total of 471 patients were enrolled into the study; 466
received a study drug and were thus included into the safety
analysis (FAS) (n=233 1.0 M gadobutrol group, n=233
0.5 M gadopentate group). Major protocol deviations were
recorded for 60 patients. The most common major
deviations were related to MRI or CT examinations, e.g.,
MR images were recorded without mandatory precontrast
sequences. Therefore, 406 patients (n=200 1.0 M gadobu-
trol; n=206 0.5 M gadopentate; demography and baseline
characteristics in Table 1) concluded the study without
major protocol deviations and were included into the
efficacy evaluation (PPS). There are no relevant differences
between both groups regarding the listed characteristics.
Table 2 shows the distribution of SOT procedures in both
groups, whereas Table 3 shows the distribution of diseases.
On the patient level the disease distribution (benign/
malignant) is fairly balanced between the treatment groups;
a slight imbalance can be seen in the disease distribution on
the lesion level. In about 75% of the benign cases in both
treatment groups, the lesions consisted of single cysts.
Accuracy
For the average reader, the ‘mean’ accuracy rates for the
combined assessment of precontrast and postcontrast
images are 83.7% for 1.0 M gadobutrol and 87.3% for
0.5 M gadopentate dimeglumine. The differences between
the gadobutrol and the gadopentate group ranged between
less than 2% and 8% for the three readers. Statistical
significance of noninferiority according to the predefined
difference of <10% was achieved for the average reader
and reader 1. The full data set is displayed in Fig. 1.
Almost identical increases in diagnostic accuracy from
precontrast to combined assessment of precontrast and
contrast-enhanced MRI sequences in comparison to the
SOT were obtained for 1.0 M gadobutrol and 0.5 M
gadopentate with differences between the two contrast agents
of maximum 3% (in favor of gadobutrol in case of reader 1)
(Fig. 1). Statistical significance according to the predefined
difference of <4% was achieved for the average reader
(Fig. 1).
Sensitivity
Diagnostic sensitivity rates for lesion classification were
comparable between 1.0 M gadobutrol and 0.5 M
2Diagnostic sensitivity determines the rate of correctly identified
malignant lesions in comparison with the respective standard of
truth (SOT), and is defined as the number of correctly localized and
classified malignant lesions (TP) divided by the total number of
malignant SOT lesions.
3 The specificity rate for lesion classification is defined as the
number of correctly localized and classified benign lesions (TN)
divided by the total number of patients with benign SOT lesions.
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gadopentate (85.2% for 1.0 M gadobutrol and 88.7% for
0.5 M gadopentate, Fig. 2). The difference in diagnostic
sensitivity between 1.0 M gadobutrol and 0.5 M gado-
pentate ranged from 1 to 7% (Fig. 2). Both groups showed
a considerable and comparable increase of diagnostic
sensitivity from precontrast to combined precontrast and
postcontrast findings (Fig. 2).
Specificity
Diagnostic specificity rates for lesion classification were
comparable between 1.0 M gadobutrol and 0.5 M
gadopentate (82.1% vs. 86.1% for the average reader,
Fig. 3). Also the differences in diagnostic specificity from
precontrast to the combined assessment of precontrast and
contrast-enhanced MRI findings in comparison with the
standard of truth were comparable, although no relevant
increases from the precontrast to the combined precontrast
and postcontrast images were observed in either group
(Fig. 3).
Discussion
The purpose of this multicenter, randomized, interindivid-
ually controlled, single-blind study was to demonstrate
the noninferiority of 1.0 M gadobutrol in comparison with
0.5 M gadopentate in the diagnostic assessment of renal
lesions. Therefore, the accuracy of the combined precon-
trast and postcontrast images was chosen as the primary
end point, representing the relevant diagnostic information
for the physician. However, it has to be considered that this
is not the end point exclusively representing the contribu-
tion of a contrast agent.
To exclude bias in the evaluation of diagnostic efficacy
in the two treatment groups, the evaluation of the MRI
images was carried out by three experienced blinded
readers not otherwise involved in the study. To assess the
overall significance of the results across the readers,
different approaches are possible. One approach is the
‘majority read’, i.e., in the case of three readers, two of the
three need to reach significance in order for the overall
result to be classified as significant. However, the primary
objective of imaging studies is to evaluate the diagnostic
efficacy of a specific imaging modality and/or to compare
the efficacy of two modalities. The concept of the ‘average
reader’ was prospectively chosen in the study protocol to
represent the overall results and their significance.
The predefined noninferiority significance level of less
than 10% lower limit of CI was achieved for the average
reader in the PPS, confirming the noninferiority of 1.0 M
gadobutrol compared with 0.5 M gadopentate. In addition,
statistical proof of noninferiority on the basis of the
increase in diagnostic accuracy from precontrast to
combined precontrast and contrast-enhanced MRI with a
predefined noninferiority margin of 0.04 (4%) was
obtained. Conclusion of proof of noninferiority clearly
depends on the choice of the maximum acceptable
difference between the two agents. The chosen equivalence
limit in this study was based on the response rate of the
study drug. The diagnostic efficacy rate of 0.5 M
gadopentate was set to 85–90%, based on the available
literature [28, 29]. Overall, acceptable accuracy rates of
about 85% were obtained in both treatment groups in the
presented study.
Table 1 Demography and baseline characteristics (PPS)
Gadobutrol (n=200) Gadopentate (n=206) Overall (n=406)
Age (years) 61.7 (12.6) 62.9 (12.0) 62.3 (12.3)
Male 135 (67.5%) 133 (64.6%) 268 (66.0%)
Female 65 (32.5%) 73 (35.4%) 138 (34%)
Weight (kg) 78.6 (14.3) 79.0 (14.3) 78.8 (14.3)
Height (cm) 171.5 (9.1) 171.6 (8.9) 171.6 (9.0)
Table 2 Number of patients by SOT procedures (PPS)
Treatment SOT procedures
CT Nephrectomy Enucleation Surg. exploration Core biopsy Fine needle biopsy Overall
N % N % N % N % N % N % N %
Gadobutrol 185 96.86 110 57.59 25 13.09 2 1.05 2 1.05 2 1.05 191 100
Gadopentate 187 98.42 109 57.37 19 10.00 2 1.05 2 1.05 1 0.53 190 100
Overall 372 97.64 219 57.48 44 11.55 4 1.05 4 1.05 3 0.79 381 100
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Hugh and Dubey proposed equivalence limits for binary
data in dependence on the response of the study drug [30].
Based on previously published literature data the upper
limit of the efficacy range for the reference drug (i.e., in our
case the accuracy of gadopentate dimeglumine MRI in the
investigated indication) was set to the demanding target of
10% for the noninferiority margin assuming a reference
accuracy of 90–95%. Gadobutrol met the predefined end
point, but it should be noted that the less demanding 15%
difference (based on a reference accuracy of 80–90%)
would have been met by all readers and the clinical
investigators as well as by the average reader. Concerning
the predefined equivalence limit for the statistical proof of
the noninferiority regarding the increase in diagnostic
accuracy, a note of caution is necessary, as the predefined
limit of 4% is obviously very strict, but not as well
referenced as the limits of the overall rate. Further
statistical research is probably necessary to arrive at
reliable guiding limits for this type of question.
However, an interesting methodological aspect surfaced
in this study. Even though the noninferiority of gadobutrol
compared with gadopentate dimeglumine was demonstra-
ted based on the results of the blinded reader evaluation,
slightly higher values for diagnostic efficacy (accuracy,
sensitivity) for combined precontrast and postcontrast
images were obtained in the gadopentate group in
comparison with the gadobutrol group. This effect was
not seen for the increase of accuracy or sensitivity from
precontrast to combined precontrast and postcontrast
between both groups. On the contrary, in the case of the
sensitivity data the gadobutrol group actually performed
consistently better, an effect which can also be seen in the
accuracy data, although to a lesser degree. This increase,
however, is the direct measure of the actual contribution of
Table 3 Distribution of disease and lesions (PPS)
SOT Gadobutrol Gadopentate
Patients with no/only benign lesions 48 (25.8%) 47 (25.1%)
Patients with at least one malignant lesion 138 (74.2%) 140 (74.9%)
Δ benign−malignant −48.4% −49.8%
Benign lesions 153 (49.7%) 170 (53.5%)
Malignant lesions 155 (50.3%) 148 (46.5%)
Δ benign−malignant −0.6% 7.0%
Accuracy of Combined Pre- and Postcontrast MRI 
Increase in Accuracy from Pre- to Combined Pre- and 
Postcontrast MRI
Gadobutrol (N=308) Gadopentate (N=318) GV-MV 95% CI Gadobutrol (N=308) Gadopentate (N=318) GV-MV 
Average Reader 83.7% 87.3% -3.7% -9.4 2.1 8.0% 6.9% 1.1% 
Clinical Study 79.9% 87.8% -7.9% -14.9 -0.9 
Reader 1 82.1% 84.6% -2.5% -9.3 4.4 11.6% 8.3% 3.3% 
Reader 2 84.4% 88.4% -4.0% -10.1 2.2 3.3% 3.0% 0.3% 
Reader 3 84.4% 89.0% -4.6% -10.8 1.6 9.0% 9.3% -0.3% 
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Fig. 1 Accuracy results for combined precontrast and postcontrast assessment as well as increase of accuracy from precontrast to
postcontrast assessment
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the contrast agent. In fact, the imbalance between the
overall accuracy in both groups using the predefined end
point (combination of precontrast and postcontrast images)
can already be seen in the precontrast evaluation alone. It
persists throughout the assessment of contrast-enhanced
MRI alone, as well as in combined assessment of
precontrast and contrast-enhanced MRI. Therefore, a
contrast-agent-related factor is considered highly unlikely
to be the cause of the observed imbalance. Potential
explanations rather include differences in the character-
istics of the two treatment groups.
Sensitivity of Combined Pre- and Postcontrast MRI 
Increase in Sensitivity from Pre- to Combined Pre- and
Postcontrast MRI 
Gadobutrol (N=155) Gadopentate (N=148) GV-MV 95% CI Gadobutrol (N=155) Gadopentate (N=148) GV-MV 
Average Reader 85.2% 88.7% -3.5% -10.5 3.4 18.7% 15.6% 3.1% 
Clinical Study 82.7% 89.9% -7.2% -15.3 0.8 
Reader 1 80.7% 85.1% -4.4% -14.1 5.1 24.0% 21.6% 2.4% 
Reader 2 90.3% 91.2% -0.9% -7.6 5.8 10.0% 6.5% 3.5% 
Reader 3 84.5% 89.9% -5.4% -13.4 2.7 22.0% 18.7% 3.3% 
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Combined Pre- and Postcontrast MRI, 
Average Reader
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100% Gadobutrol (N=155)
Gadopentate (N=148)
Increase in Sensitivity 
from Pre- to Combined Pre- and Postcontrast MRI, 
Average Reader
0%
5%
10%
15%
20%
25%
30%
Gadobutrol (N=155)
Gadopentate (N=148)
Fig. 2 Sensitivity results for combined precontrast and postcontrast assessment as well as increase of sensitivity from precontrast to
postcontrast assessment
Specificity of Combined Pre- and Postcontrast MRI 
Increase in Specificity from Pre- to Combined Pre- 
and Postcontrast MRI 
Gadobutrol (N=153) Gadopentate (N=170) GV-MV 95% CI Gadobutrol (N=153) Gadopentate (N=170) GV-MV 
Average Reader 82.1% 86.1% -4.0% -13.0 5.2 -2.7% -0.6% -2.1% 
Clinical Study 77.1% 86.0% -8.9% -19.7 2.0 
Reader 1 83.7% 84.1% -0.4% -10.2 9.3 -0.7% -3.1% -2.4% 
Reader 2 78.4% 85.9% -7.5% -18.2 3.3 -3.3% 0.0% -3.3% 
Reader 3 84.3% 88.2% -3.9% -13.0 5.2 -4.0% 1.2% -5.2% 
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Fig. 3 Specificity results for combined precontrast and postcontrast assessment as well as increase of specificity from precontrast to
postcontrast assessment
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Regarding sensitivity, considerable improvements
(>15% for the average reader) from precontrast to
postcontrast images were shown for both agents. The low
variability of these results clearly shows the add-on from
the contrast agents. Slight differences in sensitivity seen
between the two treatment groups are attributed to the
imbalance in lesion distribution between them. In the case
of specificity, on the other hand, there was actually no
added benefit of contrast enhancement in the case of both
agents. This result is not surprising, as the additional
information provided by any contrast agent in comparison
with unenhanced MRI alone is very limited in benign
lesions [31]. In more than 75% of the cases, benign lesions
consisted of single unambiguous cysts, which can be easily
diagnosed in the precontrast image. The slight difference in
specificity seen between the two agents is again attributed
to the imbalance in lesion distribution between them (more
benign lesions in the 0.5 M gadopentate group).
This study was conducted before the first report on a
potential association of gadolinium-based contrast agents
and NSF in April 2006. It has to be recognized that the
patient population investigated in this study is distinctly
different from the patient population for which NSF has been
reported (patients with severe renal impairment, most of
them on dialysis). The presence of focal kidney lesions in the
investigated study population does not directly relate to the
level of kidney function. However, exclusion of severe renal
impairment (as opposed to acute renal failure) was not a
criterion for the investigated study population. The lack of
follow-up of the patients regarding possible delayed
reactions can therefore be seen as a limitation of this study.
In conclusion, this study documents evidence for the
noninferiority of a single i.v. bolus injection of 1.0 M
gadobutrol (0.1 mmol kg−1 bw) compared with 0.5 M
gadopentate dimeglumine (0.1 mmol kg−1 bw) in the
diagnostic assessment of renal lesions with CE-MRI.
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